Featured Research

from universities, journals, and other organizations

HIV-infected Patients Should Start HAART Sooner, Study Suggests

Date:
October 30, 2008
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Under current treatment guidelines, highly active antiretroviral therapy should be considered for HIV-infected patients when their CD4+ T-cell counts fall below 350 cells per cubic millimeter (mm3). However, new epidemiological research suggests that patients with HIV may have less risk of dying if they begin HAART sooner.

Under current treatment guidelines, highly active antiretroviral therapy (HAART) should be considered for HIV-infected patients when their CD4+ T-cell counts fall below 350 cells per cubic millimeter (mm3). However, new epidemiological research suggests that patients with HIV may have less risk of dying if they begin HAART sooner.

Related Articles


HIV ravages CD4+ T-cells, one of the human immune system's primary weapons for fighting off infection. As virus levels increase in the blood, HIV-infected patients experience a decrease in CD4+ T-cells and declining health. HAART--a combination of at least three HIV medicines--is used to reduce virus levels.

Although current treatment guidelines recommend that patients begin HAART once their CD4+ T-cell counts fall below the 350 cells/mm3 threshold, the optimal time to begin therapy has been unclear because of insufficient clinical trial data. U.S. and Canadian researchers, working through the International Epidemiology Databases to Evaluate AIDS (IeDEA), set out to take steps towards establishing a clinical basis for initiating treatment.

IeDEA, a global network of clinics that serve HIV patients and collect data important to key HIV/AIDS research questions, was initiated by and is funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). IeDEA is co-funded by the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

From 1996 to 2006, the research team examined 8,374 HIV-infected study participants with CD4+ T-cell counts of 351-500 cells/mm3 who had never taken antiretroviral treatment and were free of AIDS-related illnesses. Thirty percent (2,473) of the study participants began taking HAART, while the remaining 70 percent (5,901) of participants deferred treatment until their CD4+ T-cell counts fell below 350 cells/mm3. The researchers found a 71 percent higher risk of death for patients who deferred treatment rather than initiating HAART, suggesting that therapy should begin at an earlier stage of HIV disease than currently recommended. A randomized clinical trial will be necessary to confirm this finding and support changes to established treatment guidelines.

Mari M. Kitahata, M.D., of the University of Washington in Seattle, will present the findings on October 26, 2008, during the joint annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "HIV-infected Patients Should Start HAART Sooner, Study Suggests." ScienceDaily. ScienceDaily, 30 October 2008. <www.sciencedaily.com/releases/2008/10/081027101353.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2008, October 30). HIV-infected Patients Should Start HAART Sooner, Study Suggests. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2008/10/081027101353.htm
NIH/National Institute of Allergy and Infectious Diseases. "HIV-infected Patients Should Start HAART Sooner, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/10/081027101353.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins